The full ATTAIN-1 orforglipron dataset is published in the New England Journal of Medicine, NHS tirzepatide uptake continues to exceed projections, NICE publishes final mental health and obesity guidance, and semaglutide shows promise in Parkinson's disease.

---

Orforglipron — ATTAIN-1 Full Publication in NEJM

The full 72-week results of ATTAIN-1 were published today in The New England Journal of Medicine.

Full results (72 weeks, n=3,100):

• Mean weight loss: 14.7% (orforglipron 45 mg) vs 2.1% placebo
• Dose-response relationship confirmed: 9.4% (15 mg), 11.8% (30 mg), 14.7% (45 mg)
• ≥10% weight loss: 65% (45 mg) vs 18% placebo
• ≥15% weight loss: 43% (45 mg) vs 7% placebo
• ≥20% weight loss: 22% (45 mg) vs 2% placebo
• Discontinuation due to GI events: 6.8% (vs 1.2% placebo)
• No hepatotoxicity signal

---

NHS Tirzepatide — 7-Week Update

• Cumulative patients: 56,000
• Prescribing rate: 7,200 new patients per week (stable)
• Equity data: 31% of patients from the most deprived quintile — above the national obesity prevalence distribution for this group

---

NICE — Mental Health and Obesity: Final Guidance

NICE has published final guidance on the management of mental health comorbidities in adults with obesity receiving pharmacotherapy.

Key recommendations:

1. Screen all patients for depression, anxiety, and eating disorders before initiating obesity pharmacotherapy (PHQ-9, GAD-7, SCOFF questionnaire)
2. Patients with active suicidal ideation or recent self-harm: individual risk-benefit assessment required
3. Binge eating disorder: refer for psychological intervention (CBT or DBT) before or alongside pharmacotherapy initiation
4. GLP-1 receptor agonists are not contraindicated in patients with stable depression or anxiety
5. Monitor mental health at 16-week review and annually

---

Semaglutide and Parkinson's Disease — Phase 2 Results

A Phase 2 trial of semaglutide 1 mg in patients with early Parkinson's disease (n=156) published in The Lancet Neurology showed:

• Slower progression on the MDS-UPDRS Part III motor score at 52 weeks: −3.1 points semaglutide vs +1.8 points placebo (p=0.003)
• Safety: comparable to semaglutide use in other indications; no unexpected neurological adverse events

A Phase 3 trial is being planned.

---

This update is prepared for UK healthcare professionals. All prescribing decisions should reference current NICE guidance, the BNF, and individual patient clinical assessment.